Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)”

Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China

“…When categorized by drug classes, the incidence of DRMs was 71.1% (655/921), 78.3% (721/921), 5.2% (48/921), and 3.1% (23/921) for NRTIs, NNRTIs, PIs, and INSTIs, respectively, which is consistent with the data reported previously. [ 5 , 6 ] In this survey, we found that the incidence of DRMs was the highest in patients with NNRTI-based regimens (582/664, 87.7%), followed by PI (125/196, 63.8%) and INSTI (22/31, 71.0%)-based regimens, which is consistent with previously reported incidence (50–97%) of DRMs to NNRTIs in patients who failed ART involving NNRTI-based regimens. [ 5 , 6 ] The higher incidence of DRMs against NNRTIs might be attributed to their lower resistance barrier and the frequent use as a first-line therapy.…”

“…[ 5 , 6 ] In this survey, we found that the incidence of DRMs was the highest in patients with NNRTI-based regimens (582/664, 87.7%), followed by PI (125/196, 63.8%) and INSTI (22/31, 71.0%)-based regimens, which is consistent with previously reported incidence (50–97%) of DRMs to NNRTIs in patients who failed ART involving NNRTI-based regimens. [ 5 , 6 ] The higher incidence of DRMs against NNRTIs might be attributed to their lower resistance barrier and the frequent use as a first-line therapy. We further divided the patients into three groups according to the duration of ART.…”

“…However, Dovato, a combination of 3TC/dolutegravir (DTG) in a single tablet, showed comparable efficacy in suppressing viremia even in the presence of DRMs against 3TC, possibly due to the high efficacy of DTG. [ 6 ] The incidence of DRMs in patients treated with PI-based regimens was 63.8%, which is significantly lower than in NRTI- and NNRTI-based regimens, possibly due to its high resistance barriers and efficacy. In case of INSTIs, all levels (high/mid/low) of resistance were observed for drugs (BIC, Cabotegravir (CAB), DTG, EVG, and RAL) while resistance against EVG and RAL, the most widely used, was the most common.…”